

Colgate Palmolive (India)

Accumulate



View: Volume recovery continues; Maintain Accumulate

The Q3FY19 results came in line with our expectation. On an unfavorable base of 12% volume growth the company was able to post 7% growth. After consecutive 7 quarters of lackluster volume performance, in the second successive quarter, the company was able to show improvement in volume growth. We attribute the improvement in volume performance to recent launch of Swarna Vedshakti and corrective action in natural portfolio. We believe that the company would report gradual recovery in volume growth on favorable base. In addition, the impact of increase in reach of Swarna Vedshakti would help it to garner share in the natural category. We have maintained our FY19E & FY20E earnings to ₹ 28.1 & ₹ 30.6 respectively as our hypothesis on improvement in volume growth is holding true. We have introduced FY21E EPS estimate at ₹ 33.5. Valuing stock at 45x FY21 EPS to arrive at a TP of ₹ 1,509. Maintain Accumulate.

Operational performance was in line

Net revenues jumped 6.4% YoY to ₹ 11.0bn came in line with estimate. EBITDA jumped by 11.2% YoY to ₹ 3.1bn – came in line with our estimate. The EBITDA margin expanded by 120bps to 28.6% as 10bps increase in RM cost was completely offset by 80/30/20bps decrease in Employee cost/Other expense/A&P spends during the quarter. APAT jumped 12.6% to ₹ 1.9bn – came in line with our estimate.

New launches supported growth; but margin expansion is challenge

Colgate's volume growth has improved considerably in past couple of quarters primarily driven by new launches in the naturals portfolio. The company has launched Swarna Vedshakti nationwide during last quarter is gaining significant traction. In addition, the company has relaunched its key brand Colgate Total. Further, Palmolive Facial Bar is launched in key markets, resulted in better volume growth. New advertisement campaigns 'Andar se strong' was launched during the quarter, is expected to boost volumes here on. Going ahead, we believe that the company would gain MS primarily driven by new product launch and decline in competitive pressure from Patanjali. However, the company has consistently improved its margins in past six quarters. We believe that these are peak margins and further expansion would be a challenge.

Q3FY19 Result (₹ Mn)

Particulars	Q3FY19	Q3FY18	YoY (%)	Q2FY19	QoQ (%)
Revenue	10,994	10,333	6.4	11,680	(5.9)
Total Expense	7,849	7,504	4.6	8,385	(6.4)
EBITDA	3,145	2,829	11.2	3,296	(4.6)
Depreciation	406	396	2.6	398	1.9
EBIT	2,739	2,433	12.5	2,897	(5.5)
Other Income	79	86	(7.6)	86	(8.4)
Interest	0	0		0	
EBT	2,818	2,511	12.5	2,984	(5.6)
Tax	897	812	10.4	1,020	(12.1)
RPAT	1,921	1,699	13.1	1,964	(2.2)
APAT	1,921	1,707	12.6	1,964	(2.2)
			(bps)		(bps)
Gross Margin (%)	65.1	65.2	(9)	64.8	37
EBITDA Margin (%)	28.6	27.4	123	28.2	39
NPM (%)	17.5	16.4	103	16.8	66
Tax Rate (%)	31.8	32.4	(53)	34.2	(236)
EBIT Margin (%)	24.9	23.5	136	24.8	11

CMP	₹ 1,322
Target / Upside	₹ 1,509 / 14%
BSE Sensex	36,195
NSE Nifty	10,850

Scrip Details

Equity / FV	₹ 272mn / ₹ 1
Market Cap	₹ 360bn
	US\$ 5bn
52-week High/Low	₹ 1,355/₹ 1,018
Avg. Volume (no)	518,788
NSE Symbol	COLPAL
Bloomberg Code	CLGT IN

Shareholding Pattern Dec'18(%)

Promoters	51.0
MF/Banks/FIs	11.9
FII's	13.8
Public / Others	23.3

Valuation (x)

	FY19E	FY20E	FY21E
P/E	47.0	43.2	39.4
EV/EBITDA	27.6	25.1	22.7
ROE (%)	46.9	40.2	37.0
RoACE (%)	44.0	39.5	36.5

Estimates (₹ mn)

	FY19E	FY20E	FY21E
Revenue	45,012	48,959	53,557
EBITDA	12,732	13,786	15,052
PAT	7,992	8,320	9,124
EPS (₹)	28.1	30.6	33.5

VP Research: Sachin Bobade

Tel: +91 22 40969731


E-mail: sachinb@dolatcapital.com

Associate: Nikhat Koor


Tel: +91 22 40969764

E-mail: nikhatk@dolatcapital.com




Exhibit 1: Gross Margin (%) Trend



Source: DART, Company

Exhibit 2: Strong EBITDA Margins (%)


Source: DART, Company

Exhibit 3: A&P Spends (% Of Revenues)


Source: DART, Company

Exhibit 4: Volume growth overall (% YoY)


Source: DART, Company

Profit and Loss Account

(₹ Mn)	FY18A	FY19E	FY20E	FY21E
Revenue	41,880	45,012	48,959	53,557
Total Expense	30,756	32,280	35,173	38,506
COGS	14,901	15,385	16,930	18,734
Employees Cost	3,070	3,209	3,393	3,604
Other expenses	12,786	13,686	14,850	16,167
EBIDTA	11,124	12,732	13,786	15,052
Depreciation	1,565	1,751	1,913	2,075
EBIT	9,559	10,981	11,873	12,977
Interest	0	0	0	0
Other Income	388	376	476	566
Exc. / E.O. items	(117)	341	0	0
EBT	9,830	11,698	12,350	13,543
Tax	3,097	3,706	4,030	4,419
RPAT	6,734	7,992	8,320	9,124
Minority Interest	0	0	0	0
Profit/Loss share of associates	0	0	0	0
APAT	6,850	7,651	8,320	9,124

Balance Sheet

(₹ Mn)	FY18A	FY19E	FY20E	FY21E
Sources of Funds				
Equity Capital	272	272	272	272
Minority Interest	0	0	0	0
Reserves & Surplus	14,974	18,568	22,310	26,413
Net Worth	15,246	18,840	22,582	26,685
Total Debt	0	0	0	0
Net Deferred Tax Liability	355	355	355	355
Total Capital Employed	15,601	19,196	22,937	27,040

Applications of Funds

Net Block	11,459	11,208	10,795	10,220
CWIP	1,586	1,586	1,586	1,586
Investments	311	311	311	311
Current Assets, Loans & Advances	12,282	16,470	21,439	27,056
Inventories	2,267	2,791	3,035	3,320
Receivables	2,010	1,778	1,934	2,116
Cash and Bank Balances	4,562	8,530	12,950	17,926
Loans and Advances	3,443	3,371	3,520	3,693
Other Current Assets	0	0	0	0
Less: Current Liabilities & Provisions	10,037	10,380	11,195	12,134
Payables	6,219	6,684	7,270	7,953
Other Current Liabilities	3,818	3,696	3,924	4,180
Net Current Assets	2,245	6,090	10,245	14,923
Total Assets	15,601	19,196	22,937	27,040

E – Estimates

Important Ratios

Particulars	FY18A	FY19E	FY20E	FY21E
(A) Margins (%)				
Gross Profit Margin	64.4	65.8	65.4	65.0
EBIDTA Margin	26.6	28.3	28.2	28.1
EBIT Margin	22.8	24.4	24.3	24.2
Tax rate	31.5	31.7	32.6	32.6
Net Profit Margin	16.1	17.8	17.0	17.0
(B) As Percentage of Net Sales (%)				
COGS	35.6	34.2	34.6	35.0
Employee	7.3	7.1	6.9	6.7
Other	30.5	30.4	30.3	30.2
(C) Measure of Financial Status				
Gross Debt / Equity	0.0	0.0	0.0	0.0
Interest Coverage				
Inventory days	20	23	23	23
Debtors days	18	14	14	14
Average Cost of Debt				
Payable days	54	54	54	54
Working Capital days	20	49	76	102
FA T/O	3.7	4.0	4.5	5.2
(D) Measures of Investment				
AEPS (₹)	25.2	28.1	30.6	33.5
CEPS (₹)	30.9	34.6	37.6	41.2
DPS (₹)	13.6	16.2	16.8	18.5
Dividend Payout (%)	54.1	57.5	55.0	55.0
BVPS (₹)	56.1	69.3	83.0	98.1
RoANW (%)	48.1	46.9	40.2	37.0
RoACE (%)	47.9	44.0	39.5	36.5
RoAIC (%)	90.6	101.2	115.0	135.9
(E) Valuation Ratios				
CMP (₹)	1322	1322	1322	1322
P/E	52.5	47.0	43.2	39.4
Mcap (₹ Mn)	359,557	359,557	359,557	359,557
MCap/ Sales	8.6	8.0	7.3	6.7
EV	354,995	351,027	346,607	341,630
EV/Sales	8.5	7.8	7.1	6.4
EV/EBITDA	31.9	27.6	25.1	22.7
P/BV	23.6	19.1	15.9	13.5
Dividend Yield (%)	1.0	1.2	1.3	1.4
(F) Growth Rate (%)				
Revenue	5.2	7.5	8.8	9.4
EBITDA	17.9	14.5	8.3	9.2
EBIT	18.0	14.9	8.1	9.3
PBT	15.5	19.0	5.6	9.7
APAT	18.6	11.7	8.7	9.7
EPS	18.6	11.7	8.7	9.7

Cash Flow

(₹ Mn)	FY18A	FY19E	FY20E	FY21E
CFO	7,743	9,525	10,498	11,497
CFI	(1,863)	(1,500)	(1,500)	(1,500)
CFF	(4,262)	(4,057)	(4,578)	(5,020)
FCFF	5,880	8,025	8,998	9,997
Opening Cash	2,943	4,562	8,530	12,950
Closing Cash	4,562	8,530	12,950	17,926

E – Estimates

DART RATING MATRIX

Total Return Expectation (12 Months)

Buy	> 20%
Accumulate	10 to 20%
Reduce	0 to 10%
Sell	< 0%

Rating and Target Price History



Month	Rating	TP (₹)	Price (₹)
Aug-17	Reduce	1,135	1,060
Oct-17	Reduce	1,118	1,063
Feb-18	Reduce	1,210	1,123
May-18	Accumulate	1,337	1,208
Jul-18	Accumulate	1,200	1,085
Oct-18	Accumulate	1,223	1,102

*Price as on recommendation date

DART Team

Purvag Shah	Managing Director	purvag@dolatcapital.com	+9122 4096 9747
Amit Khurana, CFA	Head of Equities	amit@dolatcapital.com	+9122 4096 9745

CONTACT DETAILS

Equity Sales	Designation	E-mail	Direct Lines
Dinesh Bajaj	VP - Equity Sales	dineshb@dolatcapital.com	+9122 4096 9709
Kartik Sadagopan	VP - Equity Sales	kartiks@dolatcapital.com	+9122 4096 9762
Kapil Yadav	VP - Equity Sales	kapil@dolatcapital.com	+9122 4096 9735
Equity Trading	Designation	E-mail	
P. Sridhar	SVP and Head of Sales Trading	sridhar@dolatcapital.com	+9122 4096 9728
Chandrakant Ware	VP - Sales Trading	chandrakant@dolatcapital.com	+9122 4096 9707
Shirish Thakkar	VP - Head Domestic Derivatives Sales Trading	shirisht@dolatcapital.com	+9122 4096 9702
Kartik Mehta	Asia Head Derivatives	kartikm@dolatcapital.com	+9122 4096 9715
Bhavin Mehta	VP - Derivatives Strategist	bhavinm@dolatcapital.com	+9122 4096 9705

Dolat Capital Market Private Limited.

Sunshine Tower, 28th Floor, Senapati Bapat Marg, Dadar (West), Mumbai 400013

Analyst(s) Certification

The research analyst(s), with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report.

I. Analyst(s) and Associate (S) holding in the Stock(s): (Nil)

II. Disclaimer:

This research report has been prepared by Dolat Capital Market Private Limited. to provide information about the company(ies) and sector(s), if any, covered in the report and may be distributed by it and/or its affiliated company(ies) solely for the purpose of information of the select recipient of this report. This report and/or any part thereof, may not be duplicated in any form and/or reproduced or redistributed without the prior written consent of Dolat Capital Market Private Limited. This report has been prepared independent of the companies covered herein. Dolat Capital Market Private Limited. and its affiliated companies are part of a multi-service, integrated investment banking, brokerage and financing group. Dolat Capital Market Private Limited. and/or its affiliated company(ies) might have provided or may provide services in respect of managing offerings of securities, corporate finance, investment banking, mergers & acquisitions, financing or any other advisory services to the company(ies) covered herein. Dolat Capital Market Private Limited. and/or its affiliated company(ies) might have received or may receive compensation from the company(ies) mentioned in this report for rendering any of the above services. Research analysts and sales persons of Dolat Capital Market Private Limited. may provide important inputs to its affiliated company(ies) associated with it. While reasonable care has been taken in the preparation of this report, it does not purport to be a complete description of the securities, markets or developments referred to herein, and Dolat Capital Market Private Limited. does not warrant its accuracy or completeness. Dolat Capital Market Private Limited. may not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. This report is provided for information only and is not an investment advice and must not alone be taken as the basis for an investment decision. The investment discussed or views expressed herein may not be suitable for all investors. The user assumes the entire risk of any use made of this information. The information contained herein may be changed without notice and Dolat Capital Market Private Limited. reserves the right to make modifications and alterations to this statement as they may deem fit from time to time. Dolat Capital Market Private Limited. and its affiliated company(ies), their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions. This report is neither an offer nor solicitation of an offer to buy and/or sell any securities mentioned herein and/or not an official confirmation of any transaction. This report is not directed or intended for distribution to, or use by any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject Dolat Capital Market Private Limited. and/or its affiliated company(ies) to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to a certain category of investors. Persons in whose possession this report may come, are required to inform themselves of and to observe such restrictions.

For U.S. Entity/ persons only: This research report is a product of Dolat Capital Market Private Limited., which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Dolat Capital Market Private Limited. only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a-6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person or entity.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Dolat Capital Market Private Limited. has entered into an agreement with a U.S. registered broker-dealer Ltd Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer/Entity as informed by Dolat Capital Market Private Limited. from time to time.

Dolat Capital Market Private Limited.

Corporate Identity Number: U65990DD1993PTC009797

Member: BSE Limited and National Stock Exchange of India Limited.

SEBI Registration No: BSE - INB010710052 & INF010710052, NSE - INB230710031& INF230710031, Research: INH000000685

Registered office: Office No. 141, Centre Point, Somnath, Daman – 396 210, Daman & Diu

Board: +9122 40969700 | Fax: +9122 22651278 | Email: research@dolatcapital.com | www.dolatresearch.com
